Medicare recently launched a new program called the Medicare Part D Senior Savings Model Program to test the impact of giving Medicare beneficiaries 65 and older an increased choice of Part D plans with no deductible and a max copay of $35 per month for insulin and fixed-ratio combination GLP-1 RAs Soliqua and Xultophy.
read more →
The FDA recently approved Wegovy, the first and only once-weekly injection for chronic weight management in adults.
read more →
Dr. Edelman clarifies how SGLTs and GLP-1s affect insulin use, and whether or not they cause hypoglycemia.
read more →
Our international panel of diabetes experts discussed highlights from the ADA’s Scientific Sessions, and lead a Q&A on some of the most important advances in diabetes.
read more →
GLP-1 RAs like Ozempic, Rybelsus, Bydureon and Trulicity are primarily used to control blood sugar in people with type 2 diabetes, but these medications have some important additional benefits, including new designations at higher doses for weight loss.
read more →
Trulicity offers a simple, once-weekly way to control type 2 diabetes and prevent cardiovascular disease (CVD) or help with existing CVD. This GLP-1 RA acts in many ways to help achieve glucose control and a healthier self. Trulicity is simply administered, you don’t ever see a needle and it doesn’t cause weight gain.
read more →
With recent news about SGLT2s and GLP-1 RAs helping to protect against heart disease in addition to their primary purpose of lowering blood sugars, Dr. Edelman addresses the question of whether it’s safe to take them together, and if they can also cause hypoglycemia.
read more →
With newer medication options available now for treating type 2 diabetes, Dr. Edelman answers a common question about how they can be included in a diabetes management regimen with regard to metformin.
read more →
The newest classes of diabetes meds to treat type 2 are pulling more than double duty, helping to better control blood sugars, protect the heart, lower body weight and prevent chronic kidney disease.
read more →
Recently approved by the FDA, Ozempic sets itself apart from other once-weekly GLP-1 RAs for type 2 diabetes by demonstrating the quickest and greatest effect in reducing blood glucose and body weight in studies. Is it right for you?
read more →